Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brown-Forman Corporation Class B (BF.B) vs Humana Inc (HUM) Price & Performance

Brown-Forman Corporation Class BTrade
Humana IncTrade

Price performance (Past 24H)

Key statistics

Brown-Forman Corporation Class B vs Humana Inc — how do they compare? Brown-Forman Corporation Class B trades at $25.18, while Humana Inc trades at $409.46 (market cap $48.84B). The key difference: Humana Inc pays a 0.87% dividend while Brown-Forman Corporation Class B pays none, and Humana Inc is trading nearer its 52-week high, Brown-Forman Corporation Class B nearer its low. Which is the better fit depends on your goals.

BF.BHUM
Sector
Consumer StaplesHealth
52-Week High
$31.26$409.42
52-Week Low
$22.80$163.67
Market Cap
$48.84B
Enterprise Value
$57.88B
Dividend Yield
0.87%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brown-Forman Corporation Class B

BF.B trades at $26.25, up 0.31% on the day, with a bearish technical signal from moving averages but mixed oscillators. Recent earnings show three consecutive beats, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst sentiment is divided, with a 25% buy rating amid cautious technical indicators.

The stock's outlook is balanced by strong earnings momentum against bearish technicals. Opportunities lie in continued earnings outperformance, while risks include weak technical trends and lack of consensus among analysts. Investors should weigh fundamental strength against near-term price pressure.

Humana Inc

Humana (HUM) trades at $406.00, up 3.51% with strong technical bullish signals and recent earnings beats. The stock shows robust revenue growth reaching $129.66 billion in 2025, though net margins have compressed to 0.82%. Analyst sentiment is mixed with 32% buy ratings but a consensus price target of $354.33 below current levels. Recent developments include Medicare Advantage margin targets and Illinois Medicaid contract wins.

The outlook remains cautious despite operational strengths. While CenterWell expansion and margin recovery plans offer upside, current valuation at 43x P/E appears stretched relative to earnings growth. Key risks include regulatory scrutiny, healthcare utilization costs, and ongoing insider trading investigations that could pressure shareholder returns.

Returns comparison

Trailing returns across standard periods

About Brown-Forman Corporation Class B

Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.

Read more on BF.B

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM